[{"id":"97d359bc-0674-4d9f-a5d6-11b5987b3936","acronym":"","url":"https://clinicaltrials.gov/study/NCT00859937","created_at":"2021-01-18T03:16:42.805Z","updated_at":"2024-07-02T16:37:11.327Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors","source_id_and_acronym":"NCT00859937","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression • KIT overexpression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression • KIT overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 03/16/2009","start_date":" 03/16/2009","primary_txt":" Primary completion: 01/30/2013","primary_completion_date":" 01/30/2013","study_txt":"","study_completion_date":"","last_update_posted":"2018-04-20"}]